company background image
ALPH

AlphaHelix Molecular Diagnostics NGM:ALPH Stock Report

Last Price

kr0.74

Market Cap

kr46.7m

7D

-24.9%

1Y

-70.3%

Updated

12 Aug, 2022

Data

Company Financials
ALPH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance6/6
Financial Health6/6
Dividends0/6

ALPH Stock Overview

AlphaHelix Molecular Diagnostics AB (publ) develops, manufactures, and sells products for PCR/QPCR.

AlphaHelix Molecular Diagnostics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AlphaHelix Molecular Diagnostics
Historical stock prices
Current Share Pricekr0.74
52 Week Highkr3.57
52 Week Lowkr0.70
Beta-0.22
1 Month Change-26.10%
3 Month Change-35.15%
1 Year Change-70.26%
3 Year Change13.23%
5 Year Change-42.95%
Change since IPO-94.11%

Recent News & Updates

Jun 02
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

ALPHSE Life SciencesSE Market
7D-24.9%1.0%0.1%
1Y-70.3%-51.8%-22.1%

Return vs Industry: ALPH underperformed the Swedish Life Sciences industry which returned -51.8% over the past year.

Return vs Market: ALPH underperformed the Swedish Market which returned -22.1% over the past year.

Price Volatility

Is ALPH's price volatile compared to industry and market?
ALPH volatility
ALPH Average Weekly Movement12.5%
Life Sciences Industry Average Movement7.9%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market4.6%

Stable Share Price: ALPH is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ALPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a12Mikael Havsjohttps://www.alphahelix.com

AlphaHelix Molecular Diagnostics AB (publ) develops, manufactures, and sells products for PCR/QPCR. It also operates as a supplier and partner for clinical laboratories and research laboratories in the Nordic region. The company provides smarter reagents, consumables, and instruments for customers in research and diagnostics.

AlphaHelix Molecular Diagnostics Fundamentals Summary

How do AlphaHelix Molecular Diagnostics's earnings and revenue compare to its market cap?
ALPH fundamental statistics
Market Capkr46.66m
Earnings (TTM)kr4.97m
Revenue (TTM)kr48.30m

9.4x

P/E Ratio

1.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALPH income statement (TTM)
Revenuekr48.30m
Cost of Revenuekr41.42m
Gross Profitkr6.88m
Other Expenseskr1.91m
Earningskr4.97m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.078
Gross Margin14.24%
Net Profit Margin10.28%
Debt/Equity Ratio2.2%

How did ALPH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ALPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALPH?

Other financial metrics that can be useful for relative valuation.

ALPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA5.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does ALPH's PE Ratio compare to its peers?

ALPH PE Ratio vs Peers
The above table shows the PE ratio for ALPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average55x
MAGLE Magle Chemoswed Holding
61.3xn/akr257.0m
GENO Genovis AB (publ.)
94.1x60.6%kr3.4b
MCAP MedCap
29.9xn/akr3.2b
ALIF B AddLife
34.7x-17.8%kr21.3b
ALPH AlphaHelix Molecular Diagnostics
9.4xn/akr46.7m

Price-To-Earnings vs Peers: ALPH is good value based on its Price-To-Earnings Ratio (9.4x) compared to the peer average (55x).


Price to Earnings Ratio vs Industry

How does ALPH's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Earnings vs Industry: ALPH is good value based on its Price-To-Earnings Ratio (9.4x) compared to the Swedish Life Sciences industry average (48.5x)


Price to Earnings Ratio vs Fair Ratio

What is ALPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ALPH's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ALPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALPH (SEK0.74) is trading below our estimate of fair value (SEK0.8)

Significantly Below Fair Value: ALPH is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is AlphaHelix Molecular Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AlphaHelix Molecular Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether AlphaHelix Molecular Diagnostics is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has AlphaHelix Molecular Diagnostics performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


55.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALPH has high quality earnings.

Growing Profit Margin: ALPH's current net profit margins (10.3%) are higher than last year (8.6%).


Past Earnings Growth Analysis

Earnings Trend: ALPH's earnings have grown significantly by 55.1% per year over the past 5 years.

Accelerating Growth: ALPH's earnings growth over the past year (117%) exceeds its 5-year average (55.1% per year).

Earnings vs Industry: ALPH earnings growth over the past year (117%) exceeded the Life Sciences industry 92.3%.


Return on Equity

High ROE: ALPH's Return on Equity (21.1%) is considered high.


Discover strong past performing companies

Financial Health

How is AlphaHelix Molecular Diagnostics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ALPH's short term assets (SEK22.2M) exceed its short term liabilities (SEK6.9M).

Long Term Liabilities: ALPH's short term assets (SEK22.2M) exceed its long term liabilities (SEK1.7M).


Debt to Equity History and Analysis

Debt Level: ALPH has more cash than its total debt.

Reducing Debt: ALPH's debt to equity ratio has reduced from 11.6% to 2.2% over the past 5 years.

Debt Coverage: ALPH's debt is well covered by operating cash flow (309.8%).

Interest Coverage: ALPH's interest payments on its debt are well covered by EBIT (121.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is AlphaHelix Molecular Diagnostics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average board tenure


CEO

Mikael Havsjo (66 yo)

no data

Tenure

kr95,000

Compensation

Mr. Mikael Havsjö serves as the Chief Executive Officer at AlphaHelix Molecular Diagnostics AB (publ) and Techtum Lab AB. He was the Chairman of AlphaHelix Molecular Diagnostics AB (publ) and has been its...


CEO Compensation Analysis

Compensation vs Market: Mikael's total compensation ($USD9.31K) is below average for companies of similar size in the Swedish market ($USD232.80K).

Compensation vs Earnings: Mikael's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: ALPH's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AlphaHelix Molecular Diagnostics AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: AlphaHelix Molecular Diagnostics AB (publ)
  • Ticker: ALPH
  • Exchange: NGM
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr46.662m
  • Shares outstanding: 63.40m
  • Website: https://www.alphahelix.com

Number of Employees


Location

  • AlphaHelix Molecular Diagnostics AB (publ)
  • Västra Finnbodavägen 4B
  • Nacka
  • Stockholm
  • Stockholm County
  • 131 30
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.